(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 23 September 2015 - Actelion Ltd (SIX: ATLN) today announced that key data from the pivotal Phase III GRIPHON study with the investigational drug selexipag (Uptravi®) will be shared through an oral presentation at the European Respiratory Society (ERS) Congress in Amsterdam, Netherlands. The oral presentation, titled 'Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results' will be given by Professor Olivier Sitbon from the Hospital Le Kremlin Bicêtre, Paris, France, at 11.15 on 30 September. The abstract can be found in the congress program online. The ERS...
↧